SunD, GaoW, HuH, ZhouS. Why 90% of clinical drug development fails and how to improve it?. Acta Pharm Sin B. 2022; 12(7):3049–3062. doi:10.1016/j.apsb.2022.02.002
2.
SpradlinJN, ZhangE, NomuraDK. Reimagining druggability using chemoproteomic platforms. Accounts of Chemical Research, 2021; 54(7):1801–1813. https://doi.org/10.1021/acs.accounts.1c00065
ChenZ, WangX, ChenXet al., Accelerating therapeutic protein design with computational approaches toward the clinical stage. Computational and Structural Biotechnology Journal. 2023; (21):2909-2926. doi: 10.1016/j.csbj.2023.04.027.
6.
SkwarkMJ, PanićJ, ElofssonA. (2023). Application of Generative AI in Drug Discovery. SpringerLink.
7.
CortialL, MonteroV, TourletSet al., Artificial intelligence in drug repurposing for rare diseases: a mini-review. Front Med, 2024; 11:1404338. doi: 10.3389/fmed.2024.1404338
8.
DanaJ, VenkatasamyA, SavianoAet al., Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. Hepatol Int. 2022; 16(3):509–522. doi:10.1007/s12072-022-10303-0
9.
ChenZ, RenX, ZhouY, HuangN. Exploring structure-based drug discovery of GPCRs beyond the orthosteric binding site. hLife, 2024:2(5);211-226.
10.
Blanco-GonzálezA, CabezónA, Seco-GonzálezAet al., The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Pharmaceuticals (Basel). 2023; 16(6):891. Published 2023Jun18. doi:10.3390/ph16060891
11.
KozlovM. ‘Publish or Perish’ is now a card game — not just an academic's life. Nature. 2024; 632(483). doi: 10.1038/d41586-024-02511-5
12.
Stanford Institute for Human-Centered AI. (2024). Data-centric AI: AI models are only as good as their data pipeline.
